Michele Schneider, chief strategist at MarketGauge, says the rise in popularity of obesity drugs are boosting a new realm of ...

Experts reevaluate coverage policies and the financial impact of antiobesity medications based on updated clinical data and ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

The latest plan to tackle obesity in the UK could also help to get people back into work, but what are the risks?

A major trial is coming to Greater Manchester to see how a new drug can tackle obesity. The ‘five-year real-world evidence study’ will be run by Health Innovation Manchester and pharmaceutical giant ...

Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares ...

Health secretary Wes Streeting has said weight-loss jabs like Wegovy could be given to those who are unemployed ...

Obesity care ‘insufficient’ as patients wait up to five years for care – report - Health leaders have called for more to be done to ensure people get the appropriate care.

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Britain’s excess pounds are weighing down our economy. As Health Secretary Wes Streeting wrote in these pages, obesity ...